专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07404953B2 Methods using eosinophil-specific apoptosis inducer 有权
标题翻译：嗜酸粒细胞特异性凋亡诱导剂的方法
公开(公告)号：US07404953B2
公开(公告)日：2008-07-29
申请号：US10204326
申请日：2001-02-15
申请人： Emi Hosaka , Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai
发明人： Emi Hosaka , Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai
IPC分类号： A61K39/395
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/28 , C07K2317/73 , C07K2317/732
摘要： The present invention provides an apoptosis inducer and a therapeutic agent for eosinophilic diseases which comprises, as an active ingredient, an antibody which reacts specifically with eosinophils and induces apoptosis of eosinophils; and a method for inducing eosinophil apoptosis using the antibody, and a method for specifically reducing or removing eosinophils in peripheral blood or tissues using the antibody.
摘要翻译：本发明提供了一种细胞凋亡诱导剂和用于嗜酸性疾病的治疗剂，其包含作为活性成分的与嗜酸性粒细胞特异性反应并诱导嗜酸性粒细胞凋亡的抗体; 以及使用该抗体诱导嗜酸性粒细胞凋亡的方法，以及使用该抗体特异性还原或除去外周血或组织中的嗜酸性粒细胞的方法。

2. 发明授权

US5939532A Humanized antibodies to ganglioside GM.sub.2 失效
公开(公告)号：US5939532A
公开(公告)日：1999-08-17
申请号：US483528
申请日：1995-06-07
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： C07K16/18 , C07K16/46 , C12P21/08 , C07K16/00 , C12N5/00 , C12P21/06
CPC分类号： C07K16/18 , C07K16/464 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

3. 发明申请

US20120177643A1 HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF 审中-公开
标题翻译：人类CDR-GRAFTED抗体及其抗体片段
公开(公告)号：US20120177643A1
公开(公告)日：2012-07-12
申请号：US13428739
申请日：2012-03-23
申请人： Kenya Shitara , Kazuyasu Nakamura , Emi Hosaka , Akiko Shimizu , Masamichi Koike
发明人： Kenya Shitara , Kazuyasu Nakamura , Emi Hosaka , Akiko Shimizu , Masamichi Koike
IPC分类号： A61K39/395 , A61P37/00 , A61P35/02 , A61P37/08 , C12N5/0783 , A61P35/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K14/7158 , C07K16/2866 , C07K2317/24 , C07K2317/565 , C07K2317/732 , G01N33/57492 , G01N33/6863 , G01N2333/4719 , G01N2333/7158
摘要： A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
摘要翻译：与人CC趋化因子受体4（CCR4）的细胞外区特异性反应但不与人血小板反应的人CDR-移植抗体或其抗体片段; 与CCR4的胞外区特异性反应并对CCR4表达细胞具有细胞毒活性的人CDR-移植抗体或其抗体片段; 以及包含至少一种抗体及其抗体片段作为活性成分的药物，治疗剂或诊断剂。

4. 发明授权

US07504104B2 Human CDR-grafted antibody and antibody fragment thereof 有权
标题翻译：人CDR移植的抗体及其抗体片段
公开(公告)号：US07504104B2
公开(公告)日：2009-03-17
申请号：US10231452
申请日：2002-08-30
申请人： Kenya Shitara , Kazuyasu Nakamura , Emi Hosaka , Akiko Tanaka , Masamichi Koike
发明人： Kenya Shitara , Kazuyasu Nakamura , Emi Hosaka , Akiko Tanaka , Masamichi Koike
IPC分类号： A61K39/395 , C12P21/08
CPC分类号： C07K16/2896 , A61K2039/505 , C07K14/7158 , C07K16/2866 , C07K2317/24 , C07K2317/565 , C07K2317/732 , G01N33/57492 , G01N33/6863 , G01N2333/4719 , G01N2333/7158
摘要： A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
摘要翻译：与人CC趋化因子受体4（CCR4）的细胞外区特异性反应但不与人血小板反应的人CDR-移植抗体或其抗体片段; 与CCR4的胞外区特异性反应并对CCR4表达细胞具有细胞毒活性的人CDR-移植抗体或其抗体片段; 以及包含至少一种抗体及其抗体片段作为活性成分的药物，治疗剂或诊断剂。

5. 发明授权

US06872392B2 Humanized antibodies 失效
标题翻译：人源化抗体
公开(公告)号：US06872392B2
公开(公告)日：2005-03-29
申请号：US10195752
申请日：2002-07-16
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： A61K38/00 , A61P35/00 , C07K16/18 , C07K16/46 , C12P21/04 , C12P21/08 , A61K39/395 , A61K39/40 , A61K39/42 , C07K16/00
CPC分类号： C07K16/3084 , A61K38/00 , C07K16/18 , C07K16/464 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , Y10S530/867
摘要： Chimeric human antibody expression vectors are constructed by inserting the heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured to produce a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but show a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.
摘要翻译：通过将分离自产生与神经节苷脂GM2反应的小鼠或大鼠单克隆抗体的杂交瘤的杂交瘤分离的重链可变区编码cDNA和抗体轻链可变区编码cDNA分别插入含有人类的表达载体来构建嵌合人抗体表达载体抗体重链恒定区或人抗体轻链恒定区编码cDNA。将表达载体导入动物细胞中，培养由此获得的转化体以产生与神经节苷脂GM2反应的嵌合人抗体。与小鼠单克隆抗体相反，本发明的嵌合人抗体不会引起患者体内的抗小鼠免疫球蛋白抗体的产生，但是显示出延长的血液半衰期，并且有不利影响的频率降低，从而可以预期例如，在治疗人类癌症的功效方面优于小鼠单克隆抗体。

6. 发明授权

US06423511B1 Humanized antibodies 失效
标题翻译：人源化抗体
公开(公告)号：US06423511B1
公开(公告)日：2002-07-23
申请号：US09393385
申请日：1999-09-10
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： C12P2104
CPC分类号： C07K16/3084 , A61K38/00 , C07K16/18 , C07K16/464 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , Y10S530/867
摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.
摘要翻译：通过将产生与神经节苷脂GM2反应的小鼠或大鼠单克隆抗体的杂交瘤分离的抗体重链可变区编码cDNA和抗体轻链可变区编码cDNA分别插入表达载体中构建嵌合人抗体表达载体，含有人抗体重链恒定区或人抗体轻链恒定区编码cDNA的动物细胞。将表达载体导入动物细胞，并将由此获得的转化体培养以产生与神经节苷脂GM2反应的嵌合人抗体。与小鼠单克隆抗体相反，本发明的嵌合人抗体不会导致患者体内的抗小鼠免疫球蛋白抗体产生，但显示出延长的血液半衰期，并且有不利影响的频率降低，从而可以预期例如，在治疗人类癌症的功效方面优于小鼠单克隆抗体。

7. 发明授权

US5874255A DNA encoding humanized antibodies specific for the ganglioside GM.sub.2 失效
标题翻译：编码针对神经节苷脂GM2的人源化抗体的DNA
公开(公告)号：US5874255A
公开(公告)日：1999-02-23
申请号：US438562
申请日：1995-05-10
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： A61K38/00 , C07K16/18 , C07K16/46 , C12N1/21 , C12N15/13 , C12P21/08 , C12P21/04 , C07H21/04 , C12N15/00
CPC分类号： C07K16/3084 , C07K16/18 , C07K16/464 , A61K38/00 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/035 , Y10S530/867
摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2.In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.
摘要翻译：通过将产生与神经节苷脂GM2反应的小鼠或大鼠单克隆抗体的杂交瘤分离的抗体重链可变区编码cDNA和抗体轻链可变区编码cDNA分别插入表达载体中构建嵌合人抗体表达载体，含有人抗体重链恒定区或人抗体轻链恒定区编码cDNA的动物细胞。将表达载体导入动物细胞，并将由此获得的转化体培养以产生与神经节苷脂GM2反应的嵌合人抗体。与小鼠单克隆抗体相反，本发明的嵌合人抗体不会导致患者体内的抗小鼠免疫球蛋白抗体产生，但显示出延长的血液半衰期，并且有不利影响的频率降低，从而可以预期例如，在治疗人类癌症的功效方面优于小鼠单克隆抗体。

8. 发明申请

US20140186349A1 HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF 审中-公开
标题翻译：人类CDR-GRAFTED抗体及其抗体片段
公开(公告)号：US20140186349A1
公开(公告)日：2014-07-03
申请号：US14215556
申请日：2014-03-17
申请人： Kenya Shitara , Kazuyasu Nakamura , Emi Hosaka , Akiko Shimizu , Masamichi Koike
发明人： Kenya Shitara , Kazuyasu Nakamura , Emi Hosaka , Akiko Shimizu , Masamichi Koike
IPC分类号： C07K16/28
CPC分类号： C07K16/2896 , A61K2039/505 , C07K14/7158 , C07K16/2866 , C07K2317/24 , C07K2317/565 , C07K2317/732 , G01N33/57492 , G01N33/6863 , G01N2333/4719 , G01N2333/7158
摘要： A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
摘要翻译：与人CC趋化因子受体4（CCR4）的细胞外区特异性反应但不与人血小板反应的人CDR-移植抗体或其抗体片段; 与CCR4的胞外区特异性反应并对CCR4表达细胞具有细胞毒活性的人CDR-移植抗体或其抗体片段; 以及包含至少一种抗体及其抗体片段作为活性成分的药物，治疗剂或诊断剂。

9. 发明申请

US20090227012A1 Human CDR-Grafted Antibody and Antibody Fragment Thereof 有权
标题翻译：人CDR-嫁接抗体及其抗体片段
公开(公告)号：US20090227012A1
公开(公告)日：2009-09-10
申请号：US12395214
申请日：2009-02-27
申请人： Kenya SHITARA , Kazuyasu Nakamura , Emi Hosaka , Akiko Tanaka , Masamichi Koike
发明人： Kenya SHITARA , Kazuyasu Nakamura , Emi Hosaka , Akiko Tanaka , Masamichi Koike
IPC分类号： C12N15/63 , C07H21/04
CPC分类号： C07K16/2896 , A61K2039/505 , C07K14/7158 , C07K16/2866 , C07K2317/24 , C07K2317/565 , C07K2317/732 , G01N33/57492 , G01N33/6863 , G01N2333/4719 , G01N2333/7158
摘要： A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
摘要翻译：与人CC趋化因子受体4（CCR4）的细胞外区特异性反应但不与人血小板反应的人CDR-移植抗体或其抗体片段; 与CCR4的胞外区特异性反应并对CCR4表达细胞具有细胞毒活性的人CDR-移植抗体或其抗体片段; 以及包含至少一种抗体及其抗体片段作为活性成分的药物，治疗剂或诊断剂。

10. 发明授权

US5830470A Humanized antibodies to ganglioside GM.sub.2 失效
公开(公告)号：US5830470A
公开(公告)日：1998-11-03
申请号：US116778
申请日：1993-09-07
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： A61K38/00 , C07K16/18 , C07K16/46 , C12N1/21 , C12N15/13 , C12P21/08 , A61K39/395 , C07H21/04 , C12P21/04
CPC分类号： C07K16/3084 , C07K16/18 , C07K16/464 , A61K38/00 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/035 , Y10S530/867
摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式